BioVie (BIVI) said late Monday it plans to sell shares and accompanying warrants in a best efforts public offering, with ThinkEquity as placement agent.
Net proceeds will be used working capital and general corporate purposes, the clinical-stage company said. Investors can also choose to buy pre-funded warrants in lieu of shares.
The shares were down nearly 50% in after-market activity.
Price: 1.4100, Change: -1.39, Percent Change: -49.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments